Maykin Ho - Jun 7, 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Role
Director
Signature
/s/ Cecelia Monoarfa-Taime, Attorney-in-fact
Stock symbol
FGEN
Transactions as of
Jun 7, 2023
Transactions value $
-$148,591
Form type
4
Date filed
6/9/2023, 07:54 PM
Previous filing
May 24, 2023
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction FGEN Common Stock Award $0 +8.29 K +26.12% $0.00 40 K Jun 7, 2023 Direct F1
transaction FGEN Common Stock Sale -$38.5 K -2.3 K -5.73% $16.79 37.7 K Jun 8, 2023 Direct F2, F3
transaction FGEN Common Stock Sale -$110 K -6.23 K -16.5% $17.68 31.5 K Jun 8, 2023 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FGEN Stock Option (Right to Buy) Award $0 +12.7 K $0.00 12.7 K Jun 7, 2023 Common Stock 12.7 K $17.13 Direct F5

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2 Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F3 Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.48 to $17.31. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.48 to $17.865. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.